新型コロナウイルス感染症に対するワクチン接種を完了した65歳以上の成人を対象に、季節性インフルエンザワクチン(SIIV)と同時投与した場合のBIMERVAX®の安全性と免疫原性を評価する第II相試験
新型コロナウイルスワクチン接種済みの65歳以上の成人を対象に、季節性表面抗原、不活化アジュバント添加インフルエンザワクチン(SIIV)と同時投与した場合のBIMERVAX®の安全性と免疫原性を評価する第II相無作為化二重盲検多施設共同試験-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
調査の概要
詳細な説明
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
The participants will be randomised 1:1:1 to one of the following three cohorts:
- Cohort 1: approximately 100 participants will receive one dose of SIIV in one arm + one dose of placebo in the other arm, at Day 0.
- Cohort 2: approximately 100 participants will receive one dose of BIMERVAX® in one arm + 1 dose of placebo in the other arm, at Day 0.
- Cohort 3: approximately 100 participants will receive one dose SIIV in one arm + one dose of BIMERVAX® in the other arm, at Day 0.
All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
A Coruña
-
A Coruña、A Coruña、スペイン、15011
- Hospital HM Modelo
-
Santiago de Compostela、A Coruña、スペイン、15706
- Hospital Clínico Universitario de Santiago
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Hospital Germans Trias i Pujol
-
Barcelona、Barcelona、スペイン、08036
- Hospital Clínic de Barcelona
-
Centelles、Barcelona、スペイン、08540
- CAP Centelles
-
-
Girona
-
Girona、Girona、スペイン、17001
- Hospital Josep Trueta
-
-
Málaga
-
Málaga、Málaga、スペイン、29010
- Hospital Regional de Málaga
-
-
Valladolid
-
Valladolid、Valladolid、スペイン、47003
- Hospital Clínico de Valladolid
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adults aged 65 or older at Day 0.
-
Are willing and able to sign the informed consent and can comply with all study visits and procedures.
-
Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0.
-
Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations.
-
Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator's judgment.
Exclusion Criteria:
-
Acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
-
Allergy to egg proteins (egg or egg products) or chicken proteins.
-
History of Guillain-Barré syndrome (GBS)
-
History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0.
-
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
-
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
-
Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
-
Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
-
Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
-
Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
-
Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
-
History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ビメルバックス + SIIV
|
One dose of booster vaccine One dose |
|
アクティブコンパレータ:ビメルバックス + プラセボ
|
One dose of booster vaccine |
|
アクティブコンパレータ:SIIV + プラセボ
|
One dose |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
時間枠:Day 0, Day 7
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7
|
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.
時間枠:Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of serious adverse events (SAEs) through the end of the study.
時間枠:Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of adverse events of special interest (AESI) through the end of the study
時間枠:Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28
時間枠:Day 0, Day28
|
To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28
時間枠:Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Influenza strain-specific HAI antibody titers at Days 0 and 28
時間枠:Day 0, Day28
|
To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX® |
Day 0, Day28
|
|
Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28
時間枠:Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®. |
Day 0, Day28
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Teresa Prat、Hipra Scientific, S.L.U
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HIPRA-HH-11
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。